Table 1.
Characteristics of suboptimal and constant statin users
| Variable | Suboptimal statin therapy | Constant statin users | Unadjusted P value |
|---|---|---|---|
| Patients (%) | 156 (15.6) | 849 (84.4) | |
| Median follow-up from V2 (mo) | 16 | 15 | .52 |
| Demographics | |||
| Age ≥ 75 y, n (%) | 39 (25.0) | 161 (19.0) | .13 |
| Men, n (%) | 102 (65.4) | 660 (77.4) | .004 |
| BMI ≥ 30, n (%) | 54 (34.6) | 292 (33.4) | .92 |
| Medical history, n (%) | |||
| Hypertension | 93 (59.6) | 490 (57.7) | .63 |
| Hyperlipidemia | 75 (48.1) | 455 (53.6) | .27 |
| Diabetes mellitus | 43 (27.6) | 43 (27.6) | .091 |
| Ever smoked | 113 (72.4) | 588 (69.3) | .42 |
| CKD (Cr > 150 μmol/L) | 13 (8.3) | 48 (5.7) | .28 |
| COPD | 13 (8.3) | 74 (8.7) | .89 |
| Prior CVD∗ | 51 (32.7) | 287 (33.8) | .82 |
| On statin before index admission | 79 (50.6) | 387 (45.6) | .30 |
| Diagnosis, n (%)† | |||
| Troponin-raised NSTE-ACS | 149 (95.5) | 828 (97.5) | .16 |
| Normal troponin NSTE-ACS | 7 (4.5) | 21 (2.5) | – |
| Treatment, n (%) | |||
| PCI/CABG | 72 (46.2) | 401 (47.2) | .80 |
| Discharged on atorvastatin 80 mg daily | 155 (99.4) | 843 (99.3) | .91 |
| NYHA functional classification at Visit 2, n (%) | |||
| Class I | 82 (52.6) | 457 (53.8) | .61 |
| Class II | 56 (35.9) | 314 (37.0) | |
| Class III | 18 (11.5) | 70 (8.3) | |
| Class IV | 0 (0.0) | 8 (0.9) | |
| Drugs at Visit 2, n (%) | |||
| Aspirin | 142 (91.0) | 795 (93.6) | .36 |
| P2Y12 inhibitor | 122 (78.2) | 738 (86.9) | .006 |
| Beta blocker | 119 (76.3) | 725 (85.4) | .016 |
| ACEI/ARB | 121 (77.6) | 706 (83.2) | .11 |
| Warfarin | 6 (3.9) | 41 (4.8) | .57 |
| Proton pump inhibitor | 67 (43.0) | 358 (42.2) | .89 |
| CYP3A4-inhibitors | 19 (12.2) | 66 (7.8) | .080 |
| Levothyroxine | 6 (3.8) | 39 (4.6) | .67 |
| Muscular symptoms at V2, n (%) | 5 (3.2) | 7 (0.8) | .020 |
ACEI, angiotensin-converting enzyme inhibitor; ARA, aldosterone receptor antagonist; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft surgery; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Cr, creatinine; CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4 drug-metabolizing enzyme; LD, loop diuretic; NSTE-ACS, non-ST elevation acute coronary syndrome; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; V2, Visit 2.
Prior CVD encompasses past myocardial infarction, stroke, transient ischemic attack or peripheral artery disease.
Raised troponin taken to indicate non-ST elevation myocardial infarction and a normal troponin unstable angina.